![]() malignancy effects and can also eliminate undesirable hematopoietic stem cells in patients with genetic disorders and autoimmune diseases, thus documenting that alloreactive effects mediated by donor lymphocytes post-grafting can play a major role in eliminating hematopoietic cell of host origin, as well as provide effective immunotherapy for the treatment of disease recurrence. However, allografts can induce effective graft vs. 2008 26:577–84.The conditioning prior to allogeneic stem cell transplantation was originally designed as a myeloablative conditioning, designed to eliminate malignant or genetically abnormal cells and then use the transplant procedure for rescue of the patients or to replace missing bone marrow products. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. Valcarcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, et al. Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. 2010 28:2859–67.Ĭhevallier P, Berceanu A, Peterlin P, Garnier A, Le Bourgeois A, Imbert BM, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, et al. Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia. Jethava YS, Sica S, Savani B, Socola F, Jagasia M, Mohty M, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. ![]() Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Grigg AP, Gibson J, Bardy PG, Reynolds J, Shuttleworth P, Koelmeyer RL, et al. Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion. 2005 106:2912–9.ĭavies JK, Taussig D, Oakervee H, Smith M, Agrawal S, Cavenagh JD, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. ![]() Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia. Nelson RP Jr, Yu M, Schwartz JE, Robertson MJ, Hromas R, Fausel CA, et al. Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia. ![]() Khawaja MR, Perkins SM, Schwartz JE, Robertson MJ, Kiel PJ, Sayar H, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O’Brien S, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S, et al. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |